BTC iShares Core MSCI Europe ETF
Respiratory Segment: AstraZeneca’s Growth Platform
AstraZeneca’s (AZN) Respiratory segment contributed 20.7% to the company’s total revenues in 2016.
Changes in AstraZeneca’s Profitability in 2Q16
AstraZeneca is reducing its selling, general, and administrative expenses for better profitability. Its R&D costs will be in line with 2015.
Performance of AstraZeneca’s RI&A Segment in 2Q16
AstraZeneca’s (AZN) respiratory, inflammation, and autoimmunity (or RI&A) segment is one of its growth platforms and a key focus area of development.
The Sweet Spot of Emerging Market Debt
While global growth statistics remain within muted expectations, EM debt and equity could remain the beneficiaries of additional capital flows for some time.
Where Should Investors Turn in the Wake of Brexit Results?
As concerns about weak economic growth are further aggravated in the aftermath of Brexit, European (EZU) stocks are likely to see downward trends for the rest of the year.
What Are the Key Risks to the Eurozone’s Growth?
The biggest risk to the Eurozone’s (EZU) (IEV) growth is Britain’s exit from the EU (European Union).
Why the Eurozone’s Recovery Isn’t Broad-Based Yet
Though there are green shoots appearing in European economies, the Eurozone’s (EZU) (VGK) growth is still facing stiff long-term headwinds.
Why the United Kingdom Should Stay in the European Union
It would be prudent for the United Kingdom (EWU)(EWUS) to continue with the European Union.